Glaucoma is one of top causes for blindness across the world. In USA alone it is second top complication which leads to blindness. Frost & Sullivan, a market research company sees significant opportunities in pharmaceutical market of glaucoma treatment. Since glaucoma is widely occurs in old people, likelihood of market expansion is greater as patients grow old.
Current eye drop treatment has not been convenient in many ways which leads to reduction in patient compliance. Difficulties in eye drops such as it cannot be self administered, greater frequency i.e. three times a day and failure to meet prescription duration mostly ends up discontinuation of treatment.
A rearch and analysis, titled as Analysis of the United States Glaucoma Pharmaceuticals Market, reckoned the market worth $2 billion for the year 2010. get more study details from here.
Drug treatment for glaucoma with higher efficacy, unique way to deliver drug in body and greater empasis on patient education for the disease could lead to remarkable success for the therapy. That is because around fifty percent patients are undiagnosed.
A strong need for a new drug treatment is felt for those who have glaucoma, because current therapies are inadequate and unable to meet goal.
There are couple of drug treatment for glaucoma in market such as prostaglandin and xalatan. Generic version of these drugs is likely to have negative impact on the market for participants in line to enter. Lack of innovations in treatment is believed to be because of the duration of the treatment which is usually for life time. Patients opts generics to make the treatment cost suitable to their budget.
The research is done by Frost & Sullivan.